Our History


First Research Paper

Dr. Guy Weinberg publishes research paper on lipid emulsion correcting cardiotoxicity caused by LAST in an animal model.


First Human Case

First case of lipid emulsion being used to treat LAST in a human. Recalling Dr. Weinberg’s paper, Dr. Meg Rosenblatt administers intravenous lipid emulsion (ILE) to a patient who had gone into cardiac arrest after being administered Bupivacaine for shoulder surgery.


ResQ Pharma, LLC

Formation of ResQ Pharma, LLC.


First Non-Opioid Drug Overdose Registry

The first registry study involving the use of lipid emulsion for non-opioid drug overdose was published with data collected from 2008-2009 on a retrospective basis.

February 2011

Correspondence with FDA

First correspondence with FDA seeking approval of a lipid emulsion product for the treatment of LAST.

August 2015

ResQ Hires CEO

ResQ hires Paul Burton as Chief Executive Officer.

August 2015

ResQ Pharma, Inc.

ResQ Pharma, LLC converts to ResQ Pharma, Inc.

September 2015

First Seed Round

ResQ completes first seed round financing at $325,000.

November 2015

Patents Secured

ResQ Pharma, Inc. acquires patents from the University of Illinois at Chicago.

September 2016

Second Seed Round

ResQ completes the second seed round financing at $739,359.

March 2017

Paper NDA

The FDA provides written guidance for ResQ Pharma to file a literature based NDA for the LAST indication.

June 2017

Orphan Drug Designation

The FDA grants ResQ Pharma’s orphan drug designation request for the treatment of LAST.

June 2017

Manufacturing Agreement

ResQ enters into a manufacturing agreement with CordenPharma Caponago.

© 2018 ResQ Pharma, Inc.